A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

PHASE3CompletedINTERVENTIONAL
Enrollment

452

Participants

Timeline

Start Date

April 3, 2020

Primary Completion Date

June 24, 2020

Study Completion Date

July 28, 2020

Conditions
COVID-19 Pneumonia
Interventions
DRUG

Tocilizumab (TCZ)

Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.

DRUG

Placebo

Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.

Trial Locations (62)

4000

Sjællands Universitetshospital, Roskilde, Roskilde

5000

Odense Universitetshospital, Odense C

10468

James J Peters Veterans Administration Medical Center - NAVREF, The Bronx

19107

Thomas Jefferson University, Philadelphia

20900

Azienda Ospedaliera San Gerardo di Monza, Monza MI

27100

Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia

27710

Duke University Medical Center, Durham

28034

Hospital Universitario La Paz, Madrid

Hospital Universitario Ramon y Cajal, Madrid

28040

Hospital General Universitario Gregorio Maranon, Madrid

28050

Hospital Universitario HM Sanchinarro-CIOCC, Madrid

30625

Medizinische Hochschule Hannover, Hanover

33136

University of Miami Miller School of Medicine, Miami

37044

CHRU de Tours, Pharmacie, Tours

40225

Universitatsklinikum Dusseldorf, Düsseldorf

44093

Hotel Dieu - Nantes, Nantes

44195

Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland

50931

Universitätsklinikum Köln; Innere Medizin I; Onkologie, Hämatologie, Cologne

55905

Mayo Clinic - PPDS, Rochester

60612

Rush University Medical Center, Chicago

60637

University of Chicago, Chicago

69004

Hôpital de La Croix Rousse, Lyon

70809

Ochsner Clinic Foundation, Baton Rouge

75013

Hopital de la Pitie Salpetriere, Paris

75014

HOPITAL COCHIN university hospital, Paris

77030

Baylor St. Luke's Medical Center, Houston

Ben Taub General Hospital - HCHD, Houston

80204

Denver Health Medical Center, Denver

80337

LMU Klinikum der Universitat Munchen, München

84143

Intermountain LDS Hospital, Salt Lake City

84770

Intermountain Medical Group, St. George

85925

Centre Hospitalier Departemental de Vendee, La Roche-sur-Yon

87042

Centre Hospitalier et Universitaire de Limoges, Limoges

90095

David Geffen School of Medicine UCLA, Los Angeles

91942

eStudySite, La Mesa

92093

University of California San Diego, La Jolla

94305

Stanford University, Stanford

98034

Evergreen Health Infectious Disease, Kirkland

98104

Swedish Hospital Medical Center, Seattle

01199

Baystate Health System, Springfield

07601

Hackensack University Medical Center, Hackensack

08901

Robert Wood Johnson University Hospital/Rutgers, New Brunswick

L8L 2X2

Hamilton General Hospital; Pharmacy, Hamilton

L8N 4A6

St. Joseph's Healthcare Hamilton, Hamilton

M5G2M9

University Health Network, Toronto

H2W 1R7

Clinical Research Institute of Montreal, Montreal

DK-2100

Rigshospitalet Copenhagen University Hospital, Copenhagen

DK-2650

Hvidovre Hospital, Hvidovre

4819 EV

Amphia Ziekenhuis, Breda

3435 CM

St. Antonius Ziekenhuis Nieuwegein, Nieuwegein

3015 GD

Erasmus MC, Rotterdam

3584 CX

Universitair Medisch Centrum Utrecht, Utrecht

08907

Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat

08035

Hospital Universitari Vall d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

G12 8TA

Greater Glasgow and Clyde Health Board, Glasgow

LS9 7AU

Leeds Teaching Hospitals NHS Trust, Leeds

NW1 2BU

University College Hospital, London

NW3 2QS

Royal Free Hospital, London

SW17 0RE

St George's Clinical Research Facility, London

W6 8RF

Imperial College London, London

M8 5RB

North Manchester General Hospital, Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04320615 - A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter